Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Interventional Cardiology
What are your key takeaways regarding the difference in findings for BETA-MI DANBLOCK and REBOOT in patients post-MI with LVEF >40%?
Related Questions
What is a reasonable protocol for how long to hold warfarin and/or DOACs before cardiac catheterization?
When is a reasonable amount of time for patients to be on 90 mg BID of ticagrelor before transitioning to 60 mg BID following PCI?
What is your stepwise approach to managing no re-flow during PCI?
What has been your approach to minimizing the risk of vascular complications when placing Impella support devices?
What advice would you give to patients with refractory nausea and vomiting at home who are unable to take oral medications but have recently had a PCI and stent placement requiring uninterrupted DAPT?
What are your top takeaways from the updated ACS guidelines that will inform changes in clinical practice?
During a coronary intervention, if the activated clotting time (ACT) is not within the therapeutic range despite administering weight-based unfractionated heparin, what alternative options do you consider?
What is your preferred duration of aggrastat therapy, and does it differ if patient presented with NSTEMI versus STEMI?
How do you manage anticoagulation/antiplatelet therapies with strong indications for uninterrupted therapy in setting of urgent procedures?
Do you always give 325mg aspirin if not already loaded with antiplatelets prior to the start of every LHC, even just for diagnostics in the absence of ACS?
